More than 25 years of professional experience as Board member of companies such as Medigene AG, Shield Therapeutics plc, WILEX AG, Immunocore ltd. and Catherex Inc. as well as Advisory roles in companies to execute exit strategies such as Suppremol GmbH, CoreOptics GmbH and Setron GmbH. Peter joined APEIRON Biologics in 2017.
Andreas Stadler holds a Master in Business Administration (Mag.) from Johannes Kepler University in Linz and is a certified accountant. Prior to joining APEIRON he worked in corporate controlling, accounting and treasury of an international logistics company.
Michael has studied biology in Mainz and Heidelberg, Germany, and holds a PhD in tumor immunology from the German Cancer Research Center in Heidelberg. He also received a MBA from Henley Management College, UK. Michael joined Apeiron as a Business Development Advisor in August 2019, looking back to almost 20 years of experience in business development & licensing in life science.
Vladimir has two decades of strategy consulting experience for large corporations in a variety of industries and countries, out of which 10 years as Managing Partner of two country entities. His specific expertise lies at the interface of new technologies, innovation and financing growth. He is author of numerous publications on the topics mentioned. Furthermore, he has also experience as a fund manager in an European early-stage Venture Capital firm. His academic background consists of studying mechanical engineering at the Technical University of Graz and Universitat Politecnica de Valencia, a Ph.D. on Corporate Venture Capital at the University of Vienna and a Machine Learning Certificate at Stanford University. Vladimir is supporting APEIRON Biologics as Strategic Advisor since March 2020.
Project Head APN301/APN311/APN401. Romana Gugenberger holds a PhD in Molecular Biology from the University of Vienna and worked several years at the Medical University of Vienna in the field of Cardiovascular Research and Tumor Biology. Since 11 years she works at APEIRON Biologics and supports non-clinical and clinical projects. At the moment she is leading the APN401 – APEIRON´s autologous cellular therapy.
Gerald Wirnsberger holds a PhD in molecular biology from the University of Vienna and has extensive research experience in immunology, genetics, cancer immunotherapy and respiratory diseases. He did his PhD at the IMP in Vienna and the LMU in Munich and did is postdoctoral work at the IMBA in Vienna. He joined APEIRON Biologics in 2017 and is employed as project head for pre-clinical and clinical projects. At the moment he is leading APN431, a small molecule project in immunotherapy and APN01, a clinical stage project in the field of respiratory diseases like COVID-19.
Has a doctoral degree in Biochemistry from the Technical University Vienna. He gained profound knowledge and expertise in pre-clinical and clinical development of small molecules and cell-therapeutics in the field of Immune Oncology at the Children’s Cancer Research Institute, Vienna and the Biotech Industry.
Sonja Höller holds a PhD in Pharmaceutical Technology and Biopharmaceutics from University of Vienna and has over 11 years of experience in Clinical Research and Development of medical devices and pharmaceuticals in the pharmaceutical industry. Thereby leading multidisciplinary clinical development projects from inception through early clinical investigations up and including clinical Phase III studies.
Since February 2020 she is working at APEIRON Biologics as Head Clinical Development, overseeing the clinical projects for APN01 and APN401.
Entrepreneur, investor, business angel ("Austrian Business Angel of the Year 2009"), and Senior Adviser to renowned global institutions (e.g. UBS Investment Bank, World Economic Forum). More than 20 years of experience in international strategic consulting as Senior Managing Partner at Roland Berger, heading Austria and Eastern Europe for more than 15 years. European Program Manager for a Computer Line at Hewlett Packard. Lecturer in Vienna respectively Munich on "Corporate Governance", "China", and "Globalization".
Austrian physician and politician. Studied Medicine and Business Administration in Vienna. Referee for ecology of the Medical Association of Austria. Member of Austrian National Assembly from 1994 until 2017.
Founder of Apeiron. Studied Medicine & Arts at the University Innsbruck, since 1990 worked as post-doctoral fellow at the Ontario Cancer Institute. Author of more than 400 publications and patents; ranked twice among top 10 most cited scientists globally. Worked for 13 years with Amgen, the Ontario Cancer Institute and University of Toronto. Former Scientific Director of the IMBA in Vienna (2002 until 2018), now Scientific Director and Professor of the Life Science Institute of the University of British Columbia.
More than 30 years entrepreneurial experience in the global life sciences business. Was managing director of Bioinvest AG in the eighties, an Austria based life science investment holding. 1988 founder of PAA Laboratories. Developed the company from a small local lab to a leading global supplier of cell culture products to the biopharmaceutical industry with subsidiaries on four continents. Sold the company to a multinational pharma corporation and became a successful investor and entrepreneur with extensive focus on the pharmaceutical and biotech industry.
Dr. Schuehsler led the creation of TVM Capital Healthcare in the United Arab Emirates in 2009, and in Singapore 2018, after he had joined the TVM Capital group of companies in Munich in 1990. Helmut has raised more than US$1bn in committed capital from more than 50 international investors, has overseen more than 120 investments in the health and life science market, and more than 50 IPOs and 30 M&A exit transactions.
A rounded finance professional, spending the first twenty years in banking where he was responsible for several derivatives trading books and then ran the European structured finance departments at J P Morgan, Credit Suisse and Bank of America. He has, in the last fifteen years, founded multiple financial businesses; including in the asset management, financial advisory and insurance underwriting arenas. For the last twenty years he has been a keen Private Equity investor in both the biotech and fintech industries and the Treasurer of Docklands Outreach, a London based charity. He holds a Masters from University College, Oxford in Politics, Philosophy and Economics and a Masters in Modern and Contemporary Literature from Birkbeck College, London.
Scientist, Keenan Research Centre for Biomedical Science, St. Michael’s Hospital; Keenan Chair in Medicine, St. Michael’s Hospital; Professor, Departments of Medicine, Biomedical Engineering and Surgery, University of Toronto; Chair, Clinical Trials Ontario
Is an Austrian haematologist, oncologist and immunologist with the main focus of research on tumour defence and stem cell transplantation. From 1990 until his retirement in 2009 he was director of the III Medical Clinic and Polyclinic at the University Medical School of the Johannes Gutenberg University Mainz. He founded Ganymed Pharmaceuticals in 2001 and with Uğur Şahin BioNTech. He was also involved in the establishment of the Institute for Translational Oncology (TRON) at the University Medical Center Mainz. Christoph has been President of the Association for Cancer Immunotherapy (CIMT) for many years and is the author of more than 200 scientific publications.
Reed and Carolee Walker Professor of Pediatrics, Human Oncology, and Genetics; Director of Research, UW Division of Pediatric Hematology, Oncology and BMT, UW Carbone Cancer Center and American Family Children’s Hospital
University of Wisconsin
Thomas has more than 15 years of experience in academic research (molecular biology and immunology), clinical practice (dermatology, clinical immunology and immune-oncology) and clinical development in the biopharmaceutical industry. He has worked in the biopharmaceutical industry for almost 15 years, holding positions in oncology drug development and medical affairs, encompassing assignments in Germany, Europe and at a global level.